Search for drugs:
Typing the drug name to query
MELPHALAN
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- Pharmacokinetic-pharmacodynamic analysis showed that Evomela administration increased heart rate-corrected QT interval. The mean change from baseline for QTcF at the mean Cmax of 4701 ng/mL was 8.0 msec. Patients treated with 200 mg/m2 Evomela showed an increase of heart rate (mean change of 7.5 bpm from baseline).
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
6
24086
Other ADRs
16030
38365557
Odds Ratio = 0.597
Drug Property Information
ATC Code(s):
- L01AA03 - melphalan
- L01AA0 -
- L01AA - Nitrogen mustard analogues
- L01A - ALKYLATING AGENTS
- L01 - ANTINEOPLASTIC AGENTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:MELPHALAN HYDROCHLORIDE
Active Ingredient UNII:1VXP4V453T
Drugbank ID:DB01042
PubChem Compound:460612
CTD ID:D008558
PharmGKB:PA450354
CAS Number:148-82-3
Dosage Form(s):injection, powder, lyophilized, for solution
Route(s) Of Administrator:intravenous
Daily Dose:
Chemical Structure: 
SMILE Code:
N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.